Unknown

Dataset Information

0

Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.


ABSTRACT: Colon cancer is still the third most common cancer which has a high mortality but low five-year survival rate. Novel tyrosine kinase inhibitors (TKI) such as pazopanib become effective antineoplastic agents that show promising clinical activity in a variety of carcinoma, including colon cancer. However, the precise underlying mechanism against tumor is unclear. Here, we demonstrated that pazopanib promoted colon cancer cell apoptosis through inducing PUMA expression. Pazopanib induced p53-independent PUMA activation by inhibiting PI3K/Akt signaling pathway, thereby activating Foxo3a, which subsequently bound to the promoter of PUMA to activate its transcription. After induction, PUMA activated Bax and triggered the intrinsic mitochondrial apoptosis pathway. Furthermore, administration of pazopanib highly suppressed tumor growth in a xenograft model. PUMA deletion in cells and tumors led to resistance of pazopanib, indicating PUMA-mediated pro-apoptotic and anti-tumor effects in vitro and in vivo. Combing pazopanib with some conventional or novel drugs, produced heightened and synergistic antitumor effects that were associated with potentiated PUMA induction via different pathways. Taken together, these results establish a critical role of PUMA in mediating the anticancer effects of pazopanib in colon cancer cells and provide the rationale for clinical evaluation.

SUBMITTER: Zhang L 

PROVIDER: S-EPMC5356882 | biostudies-other | 2017 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.

Zhang Lingling L   Wang Huanan H   Li Wei W   Zhong Juchang J   Yu Rongcheng R   Huang Xinfeng X   Wang Honghui H   Tan Zhikai Z   Wang Jiangang J   Zhang Yingjie Y  

Oncotarget 20170101 2


Colon cancer is still the third most common cancer which has a high mortality but low five-year survival rate. Novel tyrosine kinase inhibitors (TKI) such as pazopanib become effective antineoplastic agents that show promising clinical activity in a variety of carcinoma, including colon cancer. However, the precise underlying mechanism against tumor is unclear. Here, we demonstrated that pazopanib promoted colon cancer cell apoptosis through inducing PUMA expression. Pazopanib induced p53-indepe  ...[more]

Similar Datasets

| S-EPMC3422222 | biostudies-literature
2012-07-19 | E-GEOD-38008 | biostudies-arrayexpress
| S-EPMC3651803 | biostudies-literature
| S-EPMC4814203 | biostudies-literature
| S-ECPF-GEOD-38008 | biostudies-other
| S-EPMC7656541 | biostudies-literature
| S-EPMC4079733 | biostudies-literature
2012-07-20 | GSE38008 | GEO
| S-EPMC6526947 | biostudies-literature
| S-EPMC3823684 | biostudies-literature